JP2024520897A5 - - Google Patents
Info
- Publication number
- JP2024520897A5 JP2024520897A5 JP2023569774A JP2023569774A JP2024520897A5 JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5 JP 2023569774 A JP2023569774 A JP 2023569774A JP 2023569774 A JP2023569774 A JP 2023569774A JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystal
- pharmaceutical composition
- ray powder
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188833P | 2021-05-14 | 2021-05-14 | |
| US63/188,833 | 2021-05-14 | ||
| PCT/US2022/029289 WO2022241278A1 (en) | 2021-05-14 | 2022-05-13 | Solid forms of a modulator of hemoglobin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520897A JP2024520897A (ja) | 2024-05-27 |
| JP2024520897A5 true JP2024520897A5 (https=) | 2025-05-01 |
Family
ID=82020064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569774A Pending JP2024520897A (ja) | 2021-05-14 | 2022-05-13 | ヘモグロビン調節因子の固体形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851424B2 (https=) |
| EP (1) | EP4337659A1 (https=) |
| JP (1) | JP2024520897A (https=) |
| KR (1) | KR20240008356A (https=) |
| CN (1) | CN117337285A (https=) |
| AR (1) | AR126649A1 (https=) |
| AU (1) | AU2022273787B2 (https=) |
| BR (1) | BR112023021606A2 (https=) |
| CA (1) | CA3219786A1 (https=) |
| MX (1) | MX2023012156A (https=) |
| TW (1) | TW202311254A (https=) |
| WO (1) | WO2022241278A1 (https=) |
| ZA (1) | ZA202309517B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250041312A1 (en) * | 2021-12-10 | 2025-02-06 | Global Blood Therapeutics, Inc. | Methods of administering a modulator of hemoglobin |
| TW202515579A (zh) * | 2023-06-13 | 2025-04-16 | 美商全球血液治療公司 | 投予血紅素的調節劑之方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| SG10201802911RA (en) * | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| HRP20220295T1 (hr) | 2018-11-19 | 2022-05-13 | Global Blood Therapeutics, Inc. | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin |
| WO2022241286A1 (en) * | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Methods of making a modulator of hemoglobin |
-
2022
- 2022-05-13 CA CA3219786A patent/CA3219786A1/en active Pending
- 2022-05-13 CN CN202280035091.5A patent/CN117337285A/zh active Pending
- 2022-05-13 EP EP22729906.2A patent/EP4337659A1/en active Pending
- 2022-05-13 JP JP2023569774A patent/JP2024520897A/ja active Pending
- 2022-05-13 KR KR1020237043235A patent/KR20240008356A/ko active Pending
- 2022-05-13 MX MX2023012156A patent/MX2023012156A/es unknown
- 2022-05-13 AU AU2022273787A patent/AU2022273787B2/en active Active
- 2022-05-13 WO PCT/US2022/029289 patent/WO2022241278A1/en not_active Ceased
- 2022-05-13 AR ARP220101301A patent/AR126649A1/es not_active Application Discontinuation
- 2022-05-13 TW TW111118076A patent/TW202311254A/zh unknown
- 2022-05-13 BR BR112023021606A patent/BR112023021606A2/pt unknown
- 2022-05-13 US US17/744,537 patent/US11851424B2/en active Active
-
2023
- 2023-10-11 ZA ZA2023/09517A patent/ZA202309517B/en unknown
- 2023-11-01 US US18/499,491 patent/US12473277B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102303052B1 (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| JP2023512174A5 (https=) | ||
| RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| JP2022096662A5 (https=) | ||
| JP2024520897A5 (https=) | ||
| JP2022536979A5 (https=) | ||
| JP2023511105A5 (https=) | ||
| ES2199353T3 (es) | Nuevos compuestos utiles como agentes neuro-protectores. | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| CN104010636B (zh) | 三环化合物、包含它们的组合物及其用途 | |
| CN101955440B (zh) | 一种阿戈美拉汀新晶型及其制备方法 | |
| ES2208444T3 (es) | Forma pulverizada de acido (s)-2-etoxi-3-(4-(2-(4- metanosulfoniloxifenil)etoxi)fenil)propanoico. | |
| TWI848241B (zh) | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物 | |
| JP2007522135A5 (https=) | ||
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| KR20190039823A (ko) | 키나아제 억제제 화합물의 다결정형(polymorphic form), 이를 함유한 약물 조성물 및 그의 제조방법과 응용 | |
| JP2022523368A5 (https=) | ||
| JP2023530785A5 (https=) | ||
| JP2023530786A5 (https=) | ||
| JP2025509830A5 (https=) | ||
| JP2024530315A5 (https=) | ||
| RU2451016C2 (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| CN1146537C (zh) | 多非利特多晶型物 | |
| JP2023528895A5 (https=) | ||
| ES2197144T3 (es) | Uso del isomero s(+) puro de fluoxetina para la preparacion de un medicamento contra la migraña. |